Characteristics and survival outcomes of 156 patients whose disease progressed after FCR therapy and 136 patients who subsequently received salvage therapy
| Characteristic . | At time of disease progression (N = 156) . | At time of first salvage treatment (N = 136) . | ||||
|---|---|---|---|---|---|---|
| n (%) . | Median survival (mo*) . | P . | n (%) . | Median survival (mo*) . | P . | |
| Age (y), median (range) | 56 y (17-85) | — | 56 y (17-76) | — | ||
| Age, y | ||||||
| <65 | 122 (78%) | 70 | <.001 | 109 (80%) | 63 | <.001 |
| 65-74 | 29 (19%) | 27 | 24 (18%) | 23 | ||
| ≥75 | 5 (3%) | 15 | 3 (2%) | 9 | ||
| Male | 117 (75%) | 51 | .54 | 103 (76%) | 42 | .53 |
| Female | 39 (25%) | 53 | 33 (24%) | 45 | ||
| First remission (REM1), y | ||||||
| <1 | 15 (10%) | 13 | <.001 | 10 (7%) | 9 | <.001 |
| 1-1.9 | 16 (10%) | 24 | 15 (11%) | 13 | ||
| 2-2.9 | 18 (12%) | 28 | 17 (13%) | 22 | ||
| 3-3.9 | 22 (14%) | 49 | 21 (15%) | 37 | ||
| 4-4.9 | 19 (12%) | 63 | 19 (14%) | 53 | ||
| 5-5.9 | 20 (13%) | 53 | 15 (11%) | 45 | ||
| ≥6 | 46 (29%) | 71% at 5 y | 39 (29%) | 64% at 5 y | ||
| Relapse Rai stage 0-2 | 104 (67%) | 54 | .41 | 89 (65%) | 43 | .50 |
| Relapse Rai stage 3-4 | 52 (33%) | 47 | 47 (35%) | 45 | ||
| Unmutated IgHV gene | 102 (79%) | 43 | .17 | 92 (79%) | 40 | .39 |
| Mutated IgHV gene | 27 (21%) | 77 | 25 (21%) | 74 | ||
| Unknown in 27 | Unknown in 19 | |||||
| Progression FISH (hierarchical) | ||||||
| 17p deletion | 21 (21%) | 33 | .04 | 21 (22%) | 29 | .10 |
| 11q deletion | 40 (40%) | 51 | 37 (39%) | 42 | ||
| Trisomy 12 | 9 (9%) | 77 | 9 (10%) | 63 | ||
| Negative panel | 17 (17%) | 63% at 5 y | 15 (16%) | 56% at 5 y | ||
| 13q deletion | 13 (13%) | 82 | 11 (12%) | 82 | ||
| Unknown in 56 | Unknown in 43 | |||||
| Salvage hemoglobin <0 g/dL | — | — | — | 23 (19%) | 22 | .22 |
| Salvage hemoglobin ≥10 g/dL | — | — | 101 (81%) | 45 | ||
| Unknown in 12 | ||||||
| Salvage WCC <100 × 109/L | — | — | — | 102 (82%) | 47 | .71 |
| Salvage WCC ≥100 × 109/L | — | — | 22 (18%) | 38 | ||
| Unknown in 12 | ||||||
| Salvage PLT <50 × 109/L | — | — | — | 15 (12%) | 13 | <.001 |
| Salvage PLT 50-99 × 109/L | — | — | 37 (30%) | 55 | ||
| Salvage PLT ≥100 × 109/L | — | — | 72 (58%) | 63 | ||
| Unknown in 12 | ||||||
| Salvage β2m <2 × ULN | — | — | — | 57 (53%) | 63 | .009 |
| Salvage β2m ≥2 × ULN | — | — | 50 (47%) | 37 | ||
| Unknown in 29 | ||||||
| Salvage regimen | ||||||
| FCR-based | — | — | — | 60 (44%) | 66 | .013 |
| Rituximab-based | — | — | 31 (23%) | 36 | ||
| Alemtuzumab-based | — | — | 15 (11%) | 28 | ||
| Intensive chemotherapy | — | — | 8 (6%) | 8 | ||
| Lenalidomide-based | — | — | 12 (9%) | 63 | ||
| Other regimens | — | — | 10 (7%) | 37 | ||
| Characteristic . | At time of disease progression (N = 156) . | At time of first salvage treatment (N = 136) . | ||||
|---|---|---|---|---|---|---|
| n (%) . | Median survival (mo*) . | P . | n (%) . | Median survival (mo*) . | P . | |
| Age (y), median (range) | 56 y (17-85) | — | 56 y (17-76) | — | ||
| Age, y | ||||||
| <65 | 122 (78%) | 70 | <.001 | 109 (80%) | 63 | <.001 |
| 65-74 | 29 (19%) | 27 | 24 (18%) | 23 | ||
| ≥75 | 5 (3%) | 15 | 3 (2%) | 9 | ||
| Male | 117 (75%) | 51 | .54 | 103 (76%) | 42 | .53 |
| Female | 39 (25%) | 53 | 33 (24%) | 45 | ||
| First remission (REM1), y | ||||||
| <1 | 15 (10%) | 13 | <.001 | 10 (7%) | 9 | <.001 |
| 1-1.9 | 16 (10%) | 24 | 15 (11%) | 13 | ||
| 2-2.9 | 18 (12%) | 28 | 17 (13%) | 22 | ||
| 3-3.9 | 22 (14%) | 49 | 21 (15%) | 37 | ||
| 4-4.9 | 19 (12%) | 63 | 19 (14%) | 53 | ||
| 5-5.9 | 20 (13%) | 53 | 15 (11%) | 45 | ||
| ≥6 | 46 (29%) | 71% at 5 y | 39 (29%) | 64% at 5 y | ||
| Relapse Rai stage 0-2 | 104 (67%) | 54 | .41 | 89 (65%) | 43 | .50 |
| Relapse Rai stage 3-4 | 52 (33%) | 47 | 47 (35%) | 45 | ||
| Unmutated IgHV gene | 102 (79%) | 43 | .17 | 92 (79%) | 40 | .39 |
| Mutated IgHV gene | 27 (21%) | 77 | 25 (21%) | 74 | ||
| Unknown in 27 | Unknown in 19 | |||||
| Progression FISH (hierarchical) | ||||||
| 17p deletion | 21 (21%) | 33 | .04 | 21 (22%) | 29 | .10 |
| 11q deletion | 40 (40%) | 51 | 37 (39%) | 42 | ||
| Trisomy 12 | 9 (9%) | 77 | 9 (10%) | 63 | ||
| Negative panel | 17 (17%) | 63% at 5 y | 15 (16%) | 56% at 5 y | ||
| 13q deletion | 13 (13%) | 82 | 11 (12%) | 82 | ||
| Unknown in 56 | Unknown in 43 | |||||
| Salvage hemoglobin <0 g/dL | — | — | — | 23 (19%) | 22 | .22 |
| Salvage hemoglobin ≥10 g/dL | — | — | 101 (81%) | 45 | ||
| Unknown in 12 | ||||||
| Salvage WCC <100 × 109/L | — | — | — | 102 (82%) | 47 | .71 |
| Salvage WCC ≥100 × 109/L | — | — | 22 (18%) | 38 | ||
| Unknown in 12 | ||||||
| Salvage PLT <50 × 109/L | — | — | — | 15 (12%) | 13 | <.001 |
| Salvage PLT 50-99 × 109/L | — | — | 37 (30%) | 55 | ||
| Salvage PLT ≥100 × 109/L | — | — | 72 (58%) | 63 | ||
| Unknown in 12 | ||||||
| Salvage β2m <2 × ULN | — | — | — | 57 (53%) | 63 | .009 |
| Salvage β2m ≥2 × ULN | — | — | 50 (47%) | 37 | ||
| Unknown in 29 | ||||||
| Salvage regimen | ||||||
| FCR-based | — | — | — | 60 (44%) | 66 | .013 |
| Rituximab-based | — | — | 31 (23%) | 36 | ||
| Alemtuzumab-based | — | — | 15 (11%) | 28 | ||
| Intensive chemotherapy | — | — | 8 (6%) | 8 | ||
| Lenalidomide-based | — | — | 12 (9%) | 63 | ||
| Other regimens | — | — | 10 (7%) | 37 | ||
WCC, white cell count; PLT, platelets; β2m, β2-microglobulin; ULN, upper limit of normal.
Unless otherwise stated.